HENDERSON JOHN T 4

What Happened
John T. Henderson, a director of Cytokinetics, was granted stock awards on 2026-05-27 totaling 7,152 shares. The filing shows two award entries: 2,851 shares acquired at $0.00 and a derivative award for 4,301 shares at $0.00. The $0.00 price indicates these were granted as compensation (not bought). This is an acquisition (award), not a sale.

Key Details

• Transaction date: 2026-05-27; transaction code A = Award/Grant.
• Shares reported: 2,851 shares (direct award) + 4,301 shares (derivative award) = 7,152 total.
• Price: $0.00 per share (awarded, not purchased); no cash consideration reported.
• Shares owned after transaction: not specified in the supplied filing.
• Footnotes/plan details: the provided filing does not list 10b5-1 plans, tax-withholding, vesting schedule, or other footnotes.
• Timeliness: filing date matches the report date (2026-05-27), indicating a timely Form 4 submission.

Context
A derivative award generally represents a right to receive shares in the future (for example, restricted stock units or performance shares) and typically converts to common stock when vesting or performance conditions are met. Because these are compensation awards granted at $0, they reflect pay/retention rather than a market purchase and should not be interpreted on their own as a direct bullish or bearish signal.